



AP 1614
8FW

Practitioner's Docket No. U 014295-9

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent application

of _____
Inventor(s)

for _____
Title of invention

OR

In re application of: **YUHPYNG L. CHEN**

Application No.: 09/580,287

Group No.: 1614

Filed: May 30, 2000

Examiner: Dwayne C. Jones

For: **CORTICOTROPIN RELEASING FACTOR ANTAGONISTS**

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

*(When using Express Mail, the Express Mail label number is **mandatory**;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

- ☒ with sufficient postage as first class mail.

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

37 C.F.R. 1.10*

- ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____ (**mandatory**)

Signature
CLIFFORD J. MASS

(type or print name of person certifying)

Date: May 6, 2005

* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

NOTE: 37 C.F.R. 1.98(b):

- (1) Each U.S. patent listed in an information disclosure statement must be identified by inventor, patent number, and issue date.
- (2) Each U.S. patent application published listed in an information disclosure statement shall be identified by applicant, patent application publication number, and publication date.
- (3) Each U.S. application listed in an information disclosure statement must be identified by the inventor, application number, and filing date.
- (4) Each foreign patent or published foreign patent application listed in an information disclosure statement must be identified by the country or patent office which issued the patent or published the application, an appropriate document number, and the publication date indicated on the patent or published application.
- (5) Each publication listed in an information disclosure statement must be identified by publisher, author (if any), title, relevant pages of the publication, date, and place of publication.

WARNING: No extension of time can be had under 37 C.F.R. § 1.36 (a) or (b) for filing an IDS. 37 C.F.R. § 1.97(f).

NOTE: The "filing date of a national application" under 37 C.F.R. 1.97(b) has two possible meanings. Where the filing is a direct one to the United States Patent & Trademark office, the filing is defined in 37 C.F.R. 1.53(b) as "the date on which: (1) A specification containing a description pursuant to § 1.71 and at least one claim pursuant to § 1.75; and (2) any drawing required by § 1.81(a), are filed in the Patent and Trademark Office in the name of the actual inventor or inventors as required by § 1.41." 37 C.F.R. 1.97(b)(1). On the other hand, an international application that enters the national stage occurs when the applicant has filed the documents and fees required by 35 U.S.C. § 371(c) within the periods set forth in § 1.494 or § 1.495. 35 U.S.C. § 371(c) requires the filing of the following: (1) the national fee; (2) a copy of the international application, unless already sent by the International Bureau, and an English translation if filed in another language; (3) amendments under PCT Article 19, with a translation into English if made in another language; (4) an oath or declaration; and (5) a translation into English of any annexes to the international preliminary examination report, if such annexes were made in another language. 37 C.F.R. 1.97(b)(2).

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. 1.97(b).

NOTE: "No certification or fee is due when the filing is made within the above time period. It is advisable to ensure that no Office action has been mailed if the disclosure statement is delayed until after three months from filing."

NOTE: "An information disclosure statement will be considered to have been filed on the day it was received in the Office, or on an earlier date of a mailing if accompanied by a properly executed certificate of mailing under 37 C.F.R. 1.8, or Express Mail certificate under 37 C.F.R. 1.10. An office action is mailed on the date indicated in the Office action." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

NOTE: "The term 'national application' includes continuing applications (continuations, divisions, continuations-in-part) so three-months will be measured from the actual filing date of an application as opposed [sic] to the effective date of a continuing application." Notice of April 20, 1992 (1138 O.G. 37-41, 39).

NOTE: "An action on the merits means an action which treats the patentability of the claims in an application, as opposed to only formal or procedural requirements. An action on the merits would, for example, contain a rejection or indication of allowability of a claim or claims rather than just a restriction requirements (37 C.F.R. 1.142) or just a requirement for additional fees to have a claim considered (37 C.F.R. 1.16(d)). Thus, if an application was filed on Jan. 1 and the first Office action on the merits was not mailed until six months later on July 1, the examiner would be required to consider any proper information disclosure statement filed prior to July 1." Notice of April 20, 1992 (1138 O.G. 37-41, 39).


WARNING: "A petition for suspension of action to allow applicant time to submit an information disclosure statement will be denied as failing to present good and sufficient reasons, since 37 C.F.R. 1.97 provides adequate recourse for the timely submission of prior art for consideration by the examiner." Notice of July 6, 1992 (1141 O.G. 63).

If a fee is required, please charge deposit account 12-0425.

Reg. No. 30,086

Tel. No.: (212)708-1887

Customer No.: 00140




SIGNATURE OF PRACTITIONER

CLIFFORD J. MASS
(type or print name of practitioner)

LADAS & PARRY

P.O. Address

26 WEST 61ST STREET
NEW YORK, NEW YORK 10023



Practitioner's Docket No. U 014295-9

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: YUHPYNG L. CHEN

Application No.: 09/580,287

Group No.: 1614

Filed: May 30, 2000

Examiner: Dwayne C. Jones

For: CORTICOTROPIN RELEASING FACTOR ANTAGONISTS

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

We draw the attention of the Examiner to the references listed on the attached Form PTO-1449. Copies of the references are not required, because they were already filed in U.S. applications from which earlier filing dates are claimed in this application.

Respectfully submitted,

CLIFFORD J. MASS
LADAS & PARRY LLP
26 WEST 61ST STREET
NEW YORK, NEW YORK 10023
REG. NO. 30,086(212)708-1890

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) AND 1.10

*(When using Express Mail, the Express Mail label number is mandatory;
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. Section 1.8(a)

37 C.F.R. Section 1.10

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____
(mandatory)

TRANSMISSION

☐ facsimile transmitted to the Patent and Trademark Office (703) _____

Date: May 6, 2005

Signature
CLIFFORD J. MASS
(type or print name of person certifying)

• Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

FORM PTO-1449

U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

U 014295-9

09/580,287

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

Yuhpyng L. CHEN

FILING DATE

GROUP

MAY 30, 2000

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	REFERENCE DESIGNATION	DOCUMENT NUMBER	DATE	NAME	FILING DATE IF APPROPRIATE
	AA	3,637,720	01/1972	NISHIYAMA	
	AB	4,655,824	04/1987	MENGEL ET AL.	
	AC	4,786,317	11/1988	MENGEL ET AL.	
	AD	4,925,947	05/1990	CARTWRIGHT	
	AE	5,032,168	07/1991	TURNER	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AF	0154538	03/1982	DD		
	AG	0315916	05/1989	EP		
	AH	0385720	09/1990	EP		
	AI	7900094	03/1979	WO		
	AJ	94/13643	06/1994	WO		
	AK	94/13644	06/1994	WO		
	AL	94/13661	06/1994	WO		
	AM	94/13676	06/1994	WO		
	AN	94/13677	06/1994	WO		

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

	AO	Evans, Et al., J. Am. Chem. Soc. (1989) III, pp. 1063-1072 -The Total Synthesis of the Isodityrosine-Derived Cyclic Tripeptides of 4949-III and K-13. Determination of the Absolute Configuration of K-13
	AP	Williams, et al. Solvent-assisted Ullmann Ether Synthesis, Reactions of Dihydricphenols, J. Org. Chem. 32, pp. 2501-2505 (1967)
	AQ	Schmidt, et al., Total Synthesis of 4924-III, a natural inhibitor of amino-peptidase B from Ehrlich Asates Carcinoma Cells, Tetra. Ltrs, 29(26) pp. 3227-3230 (1988)
	AR	Reagents for Organic Synthesis, Vol. I, Fieser, et al. (1972) p. 68
	AS	Reagents for Organic Synthesis, Vol. 9, Fieser, et al. (1981) pp.125

EXAMINER

DATE CONSIDERED

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO FORM 1449

U. S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

U 014295-9

09/580,287

APPLICANT

Yuhpyng L. CHEN

FILING DATE

GROUP

MAY 30, 2000

1614

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AA	95/34563	03/1995	WO		
	AB	95/33750	12/1995	WO		

OTHER ART (Including Author, Title, Date, Pertinent Dates, Etc.)

	AC	L.A. Fisher, Central Actions of Corticotropin-Releasing Factor on Autonomic Nervous Activity and Cardiovascular Functioning (1993) Corticotropin-Releasing Factor, CIBA Found. Symposium 172, pp. 243-257
	AD	M.R. Brown et al., Endocrinology 111:928 (1982)
	AE	J.M. Overton et al., Journal of the Autonomic Nervous System, 35 (1991) 43-52
	AF	M.R. Brown et al, Life Sciences, Vol. 30, No. 2, pp. 207-210 (1982)
	AG	L.S. Fisher et al., Endocrinology 110 (6), pp. 2222-2224 (1982).
	AH	C.L. Grosskreutz et al., Brain Research, 442 (1988) pp. 363-367
	AI	M.R. Brown et al., Brian Research, 280 (1983) 75079
	AJ	J.M. Overton et al., Central Nervous System Effects of CRF and Angiotensin II on Cardiac Output in Conscious Rats, J. Appl. Physiol. 69(2) pp. 788-791 (1990)
	AK	H. Lehnert et al., Neuropsychobiology, 28:54-61 (1993)
	AL	A. Wiersma et al., Brian Research, 625 (1993) 219-227
	AM	A.L. Curtis et al., Brian Res. Bulletin, Vol. 31, pp. 737-744 (1993)
	AN	Abstract of E. Rohde et al., Biochemical Pharmacology, 52(6) pp. 829-833 (1996)
	AO	R.J. Valentino et al., Brain Research, 555 (1991) p. 25-34
	AP	R.J. Valentino et al., Neuroendocrinology, 48, pp. 674-677 (1988)
	AQ	T. Nakamori et al., Am. J. Physio., 265:R834-R839 (1993)
	AR	G.S. Francis et al., Circulation, 87 (Suppl. VI): V140-V148 (1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.